Comparative Pharmacology
Head-to-head clinical analysis: KENALOG IN ORABASE versus KENALOG H.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENALOG IN ORABASE versus KENALOG H.
KENALOG IN ORABASE vs KENALOG-H
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
Triamcinolone acetonide is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, reduced prostaglandin and leukotriene synthesis, and suppression of inflammatory mediators.
Adjunctive treatment for inflammatory and ulcerative diseases of oral mucosa (e.g., aphthous ulcers, lichen planus)Topical corticosteroid for oral lesions
Allergic rhinitisAsthmaDermatitisPsoriasisRheumatic disordersAdjunctive therapy in ulcerative colitisIntralesional therapy for keloids
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
2-40 mg (0.1-1 mL) intra-articular, intralesional, or soft tissue injection; intra-articular dose depends on joint size (large joint: 10-40 mg, medium joint: 5-25 mg, small joint: 2-10 mg); repeat every 2-3 weeks as needed.
None Documented
None Documented
Terminal half-life approximately 2-5 hours following mucosal application.
The terminal elimination half-life is approximately 2-3 hours for triamcinolone acetonide. In the context of intra-articular or intralesional administration, the half-life at the site of action is prolonged due to slow release from the injection depot, providing sustained local effects.
Hepatic metabolism primarily via CYP3A4; undergoes reduction, oxidation, and conjugation.
Primarily hepatic via CYP3A4; undergoes 6β-hydroxylation and reduction.
Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%).
Renal excretion of metabolites (primarily conjugated and unconjugated) accounts for approximately 80-90% of an administered dose, with less than 5% excreted unchanged in urine. Biliary/fecal elimination accounts for the remainder, about 10-20%.
Approximately 70-90% bound to corticosteroid-binding globulin and albumin.
Approximately 68-71% bound to plasma proteins, primarily albumin.
Estimated Vd of 1.5-3.5 L/kg, reflecting extensive tissue distribution.
Volume of distribution is approximately 0.5-1.0 L/kg (mean about 0.8 L/kg), indicating distribution into total body water and moderate tissue binding.
Systemic bioavailability via oral mucosa is low but not precisely quantified; local delivery is the primary route.
Topical: bioavailability is low (approximately 1-5% through intact skin). Intramuscular: complete bioavailability (100%). Intra-articular: essentially 100% locally with negligible systemic absorption relative to dose. Oral: not available (no oral formulation for triamcinolone acetonide).
No dose adjustment required for renal impairment.
No dose adjustment required; however, use caution in patients with severe renal impairment due to potential fluid retention.
No dose adjustment required for hepatic impairment.
No specific Child-Pugh based adjustments; use caution in severe hepatic impairment due to increased risk of corticosteroid side effects.
Safety and efficacy in pediatric patients have not been established; use only if clearly needed and use the smallest effective amount.
0.03-0.2 mg/kg (1-6 mg/m²) intramuscular or intralesional; repeat every 1-3 weeks; maximum single dose 30 mg.
Use the smallest effective amount for the shortest duration due to increased potential for systemic effects with age.
Use lowest effective dose; monitor for fluid retention, hyperglycemia, and osteoporosis; consider reduced initial dose (e.g., 5-20 mg intra-articular).
No FDA black box warning.
No FDA black box warnings for KENALOG-H.
["Immunosuppression may increase susceptibility to infections","Adrenal suppression with prolonged use","Avoid use in patients with known hypersensitivity to corticosteroids","Use with caution in patients with diabetes, hypertension, or osteoporosis","Do not swallow or apply to large areas of skin"]
["May suppress hypothalamic-pituitary-adrenal axis","Increased risk of infections","Osteoporosis with long-term use","Adrenal insufficiency with abrupt withdrawal","Elevated intraocular pressure with ophthalmic use"]
["Systemic fungal infections","Hypersensitivity to triamcinolone or any component of the formulation","Viral or bacterial infections of the oral mucosa (e.g., herpes simplex)"]
["Systemic fungal infections","Hypersensitivity to triamcinolone or any component","Idiopathic thrombocytopenic purpura (ITP) for intralesional use"]
Data Pending Review
Data Pending Review
Avoid hot, spicy, or acidic foods during treatment as they may irritate the lesion. No specific food-drug interactions are known.
No known food interactions with topical triamcinolone acetonide.
Triamcinolone acetonide (KENALOG IN ORABASE) is a corticosteroid. Systemic absorption from oral mucosal application is minimal but may occur. In first trimester, corticosteroid use is associated with a small increased risk of oral clefts (odds ratio ~1.3-3.4). Second and third trimester use may cause fetal adrenal suppression, intrauterine growth restriction, and preterm birth if significant systemic exposure occurs. Topical use with minimal absorption is generally considered low risk, but theoretical risks persist.
First trimester: Significant teratogenic risk (orofacial clefts, neural tube defects, IUGR) with systemic corticosteroids. Second/third trimester: Increased risk of fetal growth restriction, adrenal suppression, and preterm birth with prolonged use. Use only if clearly needed.
Triamcinolone acetonide is excreted into human breast milk in low amounts following systemic administration. The milk-to-plasma ratio is unknown for topical oral formulation, but due to low systemic absorption, concentrations are expected to be negligible. No adverse effects on the infant have been reported with topical corticosteroids. Caution is advised with prolonged or extensive use.
Enters breast milk; M/P ratio unknown. Use with caution, monitor infant for adrenal suppression. Avoid high doses or prolonged use.
No specific dose adjustment needed for standard use of KENALOG IN ORABASE during pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered clearance) are not clinically relevant due to minimal systemic absorption. Avoid excessive application or use on large mucosal areas to minimize systemic exposure.
No standard dose adjustment guidelines; use lowest effective dose for shortest duration. Monitor for corticosteroid side effects and adjust accordingly.
Category C
Category C
Apply a thin layer to the lesion after meals and at bedtime. Do not rub in; allow to form a film. Avoid use on infected lesions unless antifungal/antibacterial coverage is provided. Use with caution in patients with diabetes, hypertension, or peptic ulcer disease due to potential systemic absorption.
Kenalog-H (triamcinolone acetonide) is a high-potency topical corticosteroid. Limit use to 2 weeks continuously to avoid skin atrophy and systemic absorption. Avoid use on face, groin, axillae, or under occlusive dressings. Monitor for adrenal suppression if used over large areas. Not for ophthalmic use.
Apply a thin layer to the affected area after meals and at bedtime.Do not rub or massage the paste into the tissue.Avoid eating or drinking immediately after application to allow the paste to adhere.Do not use if you have a fungal or bacterial infection in the mouth unless directed.Notify your doctor if symptoms persist beyond 7 days or if swelling occurs.
Apply a thin layer only to affected skin, avoid healthy skin.Do not use for longer than prescribed; overuse can cause skin thinning and stretch marks.Avoid covering the area with bandages or wraps unless directed.Wash hands after application unless treating hands.Inform your doctor if you have an infection at the application site.